Page 1220 - Clinical Immunology_ Principles and Practice ( PDFDrive )

1184 Part tEN Prevention and Therapy of Immunological Diseases

presented to physicians and patients. Clin Exp Rheumatol 18. Kessel A, Toubi E. Cyclosporine-A in severe chronic urticaria: the option
2010;28:S68–79. for long-term therapy. Allergy 2010;65:1478–82.
2. Chan ES, Cronstein BN. Molecular action of methotrexate in 19. Perl A. Emerging new pathways of pathogenesis and targets for treatment
inflammatory diseases. Arthritis Res 2002;4:266–73. in systemic lupus erythematosus and Sjogren’s syndrome. Curr Opin
3. Cronstein BN, Naime D, Ostad E. The anti-inflammatory mechanism of Rheumatol 2009;21:443–7.
methotrexate. Increased adenosine release at inflamed sites diminishes 20. Laragione T, Gulko PS. mTOR regulates the invasive properties
leukocyte accumulation in an in vivo model of inflammation. J Clin of synovial fibroblasts in rheumatoid arthritis. Mol Med 2010;16:
Invest 1993;92:2675–82. 352–8.
4. Baggott JE, Morgan SL, Sams WM, et al. Urinary adenosine and 21. Paghdal KV, Schwartz RA. Sirolimus (rapamycin): from the soil of Easter
aminoimidazole carboxamide excretion in methotrexate-treated patients Island to a bright future. J Am Acad Dermatol 2007;57:1046–50.
with psoriasis. Arch Dermatol 1999;135:813–17. 22. Hemmi H, Kaisho T, Takeuchi O, et al. Small anti-viral compounds
5. Chan ES, Montesinos MC, Fernandez P, et al. Adenosine A(2A) receptors activate immune cells via the TLR7 MyD88-dependent signaling pathway.
play a role in the pathogenesis of hepatic cirrhosis. Br J Pharmacol Nat Immunol 2002;3:196–200.
2006;148:1144–55. 23. Dahl MV. Imiquimod: an immune response modifier. J Am Acad
6. Amos RS, Pullar T, Bax DE, et al. Sulphasalazine for rheumatoid arthritis: Dermatol 2000;43:S1–5.
toxicity in 774 patients monitored for one to 11 years. Br Med J (Clin Res 24. Skinner RB Jr. Imiquimod. Dermatol Clin 2003;21:291–300.
Ed) 1986;293:420–3. 25. Imbertson LM, Beaurline JM, Couture AM, et al. Cytokine induction in
7. Lind MJ, Ardiet C. Pharmacokinetics of alkylating agents. Cancer Surv hairless mouse and rat skin after topical application of the immune
1993;17:157–88. response modifiers imiquimod and S-28463. J Invest Dermatol
8. Wolverton SE, Remlinger K. Suggested guidelines for patient monitoring: 1998;110:734–9.
hepatic and hematologic toxicity attributable to systemic dermatologic 26. Gibson SJ, Imbertson LM, Wagner TL, et al. Cellular requirements for
drugs. Dermatol Clin 2007;25:195–205, vi–ii. cytokine production in response to the immunomodulators imiquimod
9. Kremer JM, Genovese MC, Cannon GW, et al. Concomitant leflunomide and S-27609. J Interferon Cytokine Res 1995;15:537–45.
therapy in patients with active rheumatoid arthritis despite stable doses 27. Tyring S. Imiquimod applied topically: a novel immune response
of methotrexate. A randomized, double-blind, placebo-controlled trial. modifier. Skin Therapy Lett 2001;6(6):1–4.
Ann Intern Med 2002;137:726–33. 28. Ceilley RI. Mechanisms of action of topical 5-fluorouracil: review and
10. Weinblatt ME, Kremer JM, Coblyn JS, et al. Pharmacokinetics, safety, and implications for the treatment of dermatological disorders. J Dermatolog
efficacy of combination treatment with methotrexate and leflunomide in Treat 2012;23:83–9.
patients with active rheumatoid arthritis. Arthritis Rheum 29. Billich A, Bornancin F, Devay P, et al. Phosphorylation of the
1999;42:1322–8. immunomodulatory drug FTY720 by sphingosine kinases. J Biol Chem
11. Nagy SE, Andersson JP, Andersson UG. Effect of mycophenolate mofetil 2003;278:47408–15.
(RS-61443) on cytokine production: inhibition of superantigen-induced 30. Payne SG, Oskeritzian CA, Griffiths R, et al. The immunosuppressant
cytokines. Immunopharmacology 1993;26:11–20. drug FTY720 inhibits cytosolic phospholipase A2 independently of
12. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the sphingosine-1-phosphate receptors. Blood 2007;109:1077–85.
management of psoriasis and psoriatic arthritis: section 4. Guidelines of 31. Paugh SW, Cassidy MP, He H, et al. Sphingosine and its analog, the
care for the management and treatment of psoriasis with traditional immunosuppressant 2-amino-2-(2-[4-octylphenyl]ethyl)-
systemic agents. J Am Acad Dermatol 2009;61:451–85. 1,3-propanediol, interact with the CB1 cannabinoid receptor. Mol
13. Liu J, Farmer JD Jr, Lane WS, et al. Calcineurin is a common target of Pharmacol 2006;70:41–50.
cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 32. Berdyshev EV, Gorshkova I, Skobeleva A, et al. FTY720 inhibits ceramide
1991;66:807–15. synthases and up-regulates dihydrosphingosine 1-phosphate formation in
14. Baughman G, Wiederrecht GJ, Campbell NF, et al. FKBP51, a novel human lung endothelial cells. J Biol Chem 2009;284:5467–77.
T-cell-specific immunophilin capable of calcineurin inhibition. Mol Cell 33. Ando S, Amano H, Amano E, et al. FTY720 exerts a survival advantage
Biol 1995;15:4395–402. through the prevention of end-stage glomerular inflammation in
15. Wilkinson A, Ross EA, Hawkins R, et al. Measurement of true glomerular lupus-prone BXSB mice. Biochem Biophys Res Commun
filtration rate in renal transplant patients receiving cyclosporine. 2010;394:804–10.
Transplant Proc 1987;19:1739–41. 34. Tsunemi S, Iwasaki T, Kitano S, et al. Effects of the novel
16. Mihatsch MJ, Antonovych T, Bohman SO, et al. Cyclosporin A immunosuppressant FTY720 in a murine rheumatoid arthritis model.
nephropathy: standardization of the evaluation of kidney biopsies. Clin Clin Immunol 2010;136:197–204.
Nephrol 1994;41:23–32. 35. Herzinger T, Kleuser B, Schafer-Korting M, et al. Sphingosine-1-
17. Gaston RS. Chronic calcineurin inhibitor nephrotoxicity: reflections on phosphate signaling and the skin. Am J Clin Dermatol 2007;8:
an evolving paradigm. Clin J Am Soc Nephrol 2009;4:2029–34. 329–36.